The evaluation of drug interactions in preclinical stages optimizes novel drug development

Receptor 3D
David Temporal | BD Department
30 September 2021

Drug-drug interactions (DDI) are an important risk factor for polymedicated patients, as they can compromise safety and alter the efficacy of medical treatments. These interactions are usually related to drugs, however, they have also been identified between nutritional products and drugs. Hence the need to prioritize the assessment of pharmacokinetic relevant molecules, cytoplasmatic enzymes, uptake transporters, and efflux receptors. When a new drug is in development phases, it is crucial to understand metabolic interactions and optimize the compound’s therapeutic effect. The scientific community concludes that relevant pharmacokinetic DDI can occur via different mechanisms.

  • alterations in drug absorption

In oral dosage, drugs solubility and dissolution change as a consequence of altered gastric homeostasis, which affects several parameters, such as pH and time of exposure.

  • protein-binding sites displacement

Drugs also interact ambivalently with alternative compounds, present in plasma or other biologic liquids, which affect or prevent affinity to a target molecule.

  • interactions with transmembrane PROTEIN transporters

Inhibition of efflux and uptake transporters may lead to alterations in the molecules’ transfer between inner and outer cell spaces.

  • Cytoplasmatic enzymes alteration

When a studied xenobiotic strongly interacts with relevant pharmacokinetic enzymes, mostly CYP450 isoforms such as CYP3A4, it can impact organ metabolic pathways. Regulatory experts recommend the use of Caco-2 cells and genetically modified MDCKII and HEK293 cells at preclinical stages, to generate preliminary data related to DDI. Further knowledge of xenobiotic interactions with pharmacokinetic relevant transmembrane proteins, such as MDR1 (Pgp), BCRP, MATE1, MRP2, and OCT2 will facilitate posterior clinical phases and will prevent potential adverse events. ReadyCell is specialized in cell-based in vitro kits developed for scientific research, which extrapolates in vivo conditions in a ready-to-use product. In case you require additional information about cell-based kits to assess drug-drug interactions, contact our scientists at   Additional readings: Kathleen M Giacomini et al. Membrane transporters in drug development, 2010. Nat Rev Drug Discov 9:215-36 Xinfeng Zhang et al. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein, 2011. Xenobiotica 41:290-6 Xiaodong Liu.  Transporter-Mediated Drug-Drug Interactions and Their Significance, 2019. Adv Exp Med Biol 1141:241-291

Related posts

Select the right well system for your research: A comprehensive guide.

Select the right well system for your research: A comprehensive guide.

In preclinical research, the choice of the appropriate well system format – whether it’s a transwell, non-transwell, or individual transwell – can significantly impact the outcome of experiments. Selecting the correct plate is crucial to working with permeability, toxicity, drug screening, or other assays.

Presenting the last advances in transporters in Germany

Presenting the last advances in transporters in Germany

On May 15-17, the 22nd Barrier- and Transporter- days took place in Germany. At the event, Jonatan Cucala, R&D researcher at ReadyCell, presented a poster entitled “PreadyTake, an in vitro ready-to-use cell-based model to evaluate potential drug-transporter interactions.”